Poxel Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients Sep 21, 2021
Poxel to Host Conference Call for First Half 2021 Financial Results on September 23, 2021 Sep 14, 2021
Poxel Appoints Elizabeth Woo as Senior Vice President, Investor Relations, Public Relations and Corporate Communications, Based in Boston Sep 2, 2021
Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2021 Jul 21, 2021
Poxel Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Following Recent Achievements Jul 12, 2021
Poxel Presents Results of Two Clinical Studies on its Direct AMP Kinase Activator, the PXL770, at the International Liver Congress (ILC)™ 2021 Jun 25, 2021
Poxel Announces Results from June 23, 2021 Ordinary Annual and Extraordinary General Meeting Jun 24, 2021
Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan Jun 23, 2021
